Familial Cancer

, Volume 6, Issue 4, pp 445–452 | Cite as

Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families

  • Maria Henningson
  • Erika Bågeman
  • Therese Sandberg
  • Åke Borg
  • Håkan Olsson
  • Helena Jernström
Article

Abstract

BRCA1 mutations predispose to early-onset breast cancer. We previously reported an association between absence of the common IGF1 19 CA-repeat allele (IGF1-19/-19) and being a BRCA1 mutation carrier in young women from breast cancer high-risk families. Others have reported a four-fold risk of premenopausal breast cancer in women with a family history and the IGF1-19/-19 genotype. The aim of this study was to investigate whether the IGF1-19/-19 genotype was associated with being a BRCA1 mutation carrier among women from BRCA1 families. DNA was available from 268 women with known BRCA1 status from the South Swedish Health Care Region. IGF1 genotyping was successfully performed with fragment analysis in 211 women from 96 families. The IGF1-19/-19 genotype was significantly more common among BRCA1 mutation carriers (14.2%) than among non-carriers (4.8%), OR 3.3 (95%CI 1.11–9.78, = 0.03) adjusted for family clustering. We confirmed our previous finding of an association between the IGF1-19/-19 genotype and BRCA1 mutation status. Since the IGF1-19/-19 genotype in combination with OC use or multiparity confers an increased risk for early onset breast cancer in high-risk women and in women from the general population, future studies are needed to elucidate the importance of the IGF1-19/-19 genotype concerning the variability in breast cancer risk among BRCA1 mutation carriers.

Keywords

BRCA1 Breast cancer Genotype IGF1 Oral contraceptive Parity 

Abbreviations

BRCA1

Breast cancer gene 1

BRCA2

Breast cancer gene 2

CA

Cytosine-adenine

CI

Confidence interval

DNA

Deoxyribonucleic acid

Ghr

Growth hormone receptor

IGF1

Insulin-like growth factor-1 gene

IGF-1

Insulin-like growth factor-1

IGF-IR

Insulin-like growth factor-1 receptor

Igfals

IGF acid labile subunit

Igfbp2

IGF binding protein 2

IRS-1

Insulin receptor substrate 1

OC

Oral contraceptive

OR

Odds ratio

References

  1. 1.
    Wang Q, Zhang H, Fishel R, Greene MI (2000). BRCA1 and cell signaling. Oncogene 19(53):6152–6158PubMedCrossRefGoogle Scholar
  2. 2.
    Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994). ks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Lancet 343(8899):692–695PubMedCrossRefGoogle Scholar
  3. 3.
    Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56(1):265–271PubMedGoogle Scholar
  4. 4.
    Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 62(3):676–689PubMedCrossRefGoogle Scholar
  5. 5.
    Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4(9):665–676PubMedCrossRefGoogle Scholar
  6. 6.
    Jernström H, Sandberg T, Bågeman E, Borg Å, Olsson H (2005). Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 92(5):857–866PubMedCrossRefGoogle Scholar
  7. 7.
    Cleveland RJ, Gammon MD, Edmiston SN et al (2006) IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 27(4):758–765PubMedCrossRefGoogle Scholar
  8. 8.
    Bågeman E, Ingvar C, Rose C, Jernström H (2007) Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women. Br J Cancer 96(5):712–717. Feb 20; [Epub ahead of print]Google Scholar
  9. 9.
    Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76(4):1005–1026PubMedGoogle Scholar
  10. 10.
    Dickson RB, Russo J (2000) Biochemical Control of Breast Development. 2nd edn. Williams and Wilkins, PhiladelphiaGoogle Scholar
  11. 11.
    Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396PubMedCrossRefGoogle Scholar
  12. 12.
    Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11(11):1361–1368PubMedGoogle Scholar
  13. 13.
    Toniolo P, Bruning PF, Akhmedkhanov A et al (2000) Serum insulin-like growth factor-I and breast cancer Int J Cancer 88(5):828–832PubMedCrossRefGoogle Scholar
  14. 14.
    Harrela M, Koistinen H, Kaprio J et al (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98(11):2612–2615PubMedCrossRefGoogle Scholar
  15. 15.
    Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U (1996) Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81(5):1791–1797PubMedCrossRefGoogle Scholar
  16. 16.
    Weber JL, May PE (1989) Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 44(3):388–396PubMedGoogle Scholar
  17. 17.
    Rosen CJ, Kurland ES, Vereault D et al (1998) Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83(7):2286–2290PubMedCrossRefGoogle Scholar
  18. 18.
    Schildkraut JM, Demark-Wahnefried W, Wenham RM et al (2005) IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 14(2):403–408PubMedCrossRefGoogle Scholar
  19. 19.
    Jernström H, Chu W, Vesprini D et al. (2001) Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 72(2):144–154PubMedCrossRefGoogle Scholar
  20. 20.
    Tae HJ, Luo X, Kim KH (1994) Roles of CCAAT/enhancer-binding protein and its binding site on repression and derepression of acetyl-CoA carboxylase gene. J Biol Chem 269(14):10475–10484PubMedGoogle Scholar
  21. 21.
    Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274(19):13176–13180PubMedCrossRefGoogle Scholar
  22. 22.
    Figer A, Karasik YP, Baruch RG et al (2002) Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women. Isr Med Assoc J 4(10):759–762PubMedGoogle Scholar
  23. 23.
    Jernström H, Deal C, Wilkin F et al. (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10(4):377–384PubMedGoogle Scholar
  24. 24.
    Jernström H, Barrett-Connor E (1999) Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 8(10):1265–1272PubMedGoogle Scholar
  25. 25.
    Narod SA, Dube MP, Klijn J et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94(23):1773–1779PubMedGoogle Scholar
  26. 26.
    Weber F, Shen L, Fukino K et al (2006) Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet 78(6):961–972PubMedCrossRefGoogle Scholar
  27. 27.
    Warner E, Foulkes W, Goodwin P et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247PubMedCrossRefGoogle Scholar
  28. 28.
    Anglian Breast Cancer Study Group. (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRefGoogle Scholar
  29. 29.
    Frayling TM, Hattersley AT, McCarthy A et al (2002) A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations Diabetes 51(7):2313–2316PubMedCrossRefGoogle Scholar
  30. 30.
    Jernström H, Johannsson O, Borg Å, Ivarsson H, Olsson H (1998) BRCA1-positive patients are small for gestational age compared with their unaffected relatives. Eur J Cancer 34(3):368–371PubMedCrossRefGoogle Scholar
  31. 31.
    Vaessen N, Janssen JA, Heutink P et al (2002) Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 359(9311):1036–1037PubMedCrossRefGoogle Scholar
  32. 32.
    Turner BC, Haffty BG, Narayanan L et al (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57(15):3079–3083PubMedGoogle Scholar
  33. 33.
    Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93(24):1852–1857PubMedCrossRefGoogle Scholar
  34. 34.
    Abramovitch S, Glaser T, Ouchi T, Werner H (2003) BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 541(1–3):149–154PubMedCrossRefGoogle Scholar
  35. 35.
    Shukla V, Coumoul X, Cao L et al (2006) Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res 66(14):7151–7157PubMedCrossRefGoogle Scholar
  36. 36.
    Russo J, Romero AL, Russo IH (1994) Architectural pattern of the normal and cancerous breast under the influence of parity. Cancer Epidemiol Biomarkers Prev 3(3):219–224PubMedGoogle Scholar
  37. 37.
    Russo J, Russo IH (1997) Toward a unified concept of mammary carcinogenesis. Prog Clin Biol Res 396:1–16PubMedGoogle Scholar
  38. 38.
    Jernström H, Lerman C, Ghadirian P et al (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354(9193):1846–1850PubMedCrossRefGoogle Scholar
  39. 39.
    King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  • Maria Henningson
    • 1
  • Erika Bågeman
    • 1
  • Therese Sandberg
    • 1
  • Åke Borg
    • 1
  • Håkan Olsson
    • 2
  • Helena Jernström
    • 1
  1. 1.Department of Oncology, Clinical SciencesLund UniversityLundSweden
  2. 2.Departments of Oncology and Cancer Epidemiology, Clinical SciencesLund UniversityLundSweden

Personalised recommendations